<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Multidrug regimens in <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV disease</z:e> are associated with an increased incidence of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, by as much as 50% </plain></SENT>
<SENT sid="1" pm="."><plain>Not only does <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> predisposes subjects to <z:mp ids='MP_0002055'>diabetes</z:mp> but also it is associated with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Previous studies suggest that <z:chebi fb="0" ids="50369">chromium picolinate</z:chebi> can improve <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The objective was to study the efficacy and safety of <z:chebi fb="0" ids="50369">chromium picolinate</z:chebi> as a treatment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in subjects infected with HIV </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The ability of <z:chebi fb="0" ids="50369">chromium picolinate</z:chebi> (1000 mug/day) to improve insulin sensitivity, determined with a hyperinsulinaemic-euglycaemic insulin clamp, was determined in eight HIV-positive subjects on highly active antiretroviral therapy </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The mean rate of <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal during the clamp was 4.41 mg <z:chebi fb="105" ids="17234">glucose</z:chebi>/kg lean body mass (LBM)/min (range 2.67-5.50), which increased to 6.51 mg/kg LBM/min (range 3.19-12.78, p = .03), an increase of 25% after 8 weeks of treatment with <z:chebi fb="0" ids="50369">chromium picolinate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>There were no significant changes in blood parameters, HIV <z:mp ids='MP_0001799'>viral</z:mp> burden or CD4+ lymphocytes with <z:chebi fb="0" ids="50369">chromium picolinate</z:chebi> treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Two subjects experienced abnormalities of liver function during the study </plain></SENT>
<SENT sid="8" pm="."><plain>Another subject experienced an elevation in blood <z:chebi fb="20" ids="16199">urea</z:chebi> nitrogen </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The study shows that <z:chebi fb="0" ids="50369">chromium picolinate</z:chebi> therapy improves <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in some HIV-positive subjects, but with some concerns about safety in this population </plain></SENT>
</text></document>